Ebert Jay R, Smith Anne, Fallon Michael, Butler Rodney, Nairn Robert, Breidahl William, Wood David J
School of Sport Science, Exercise and Health, University of Western Australia, Crawley, Perth, Australia
School of Physiotherapy and Curtin Health Innovation Research Institute, Curtin University, Bentley, Perth, Australia.
Am J Sports Med. 2015 Sep;43(9):2208-15. doi: 10.1177/0363546515591257. Epub 2015 Jul 10.
Graft hypertrophy is a common occurrence after periosteal, collagen-covered and matrix-induced autologous chondrocyte implantation (MACI).
PURPOSE/HYPOTHESIS: The purpose of this study was to investigate the incidence, development, and degree of graft hypertrophy at 24 months after MACI. The hypothesis was that graft hypertrophy would not be associated with clinical outcome at 24 months.
Case series, Level of evidence, 4.
This study was undertaken in 180 consecutive patients (113 male, 67 female) after MACI in the knee. All patients were assessed clinically using the Knee injury and Osteoarthritis Outcome Score (KOOS) and underwent magnetic resonance imaging (MRI) at 3, 12, and 24 months after surgery. The incidence of hypertrophy relevant to anatomic graft site was investigated, as was the progressive change in hypertrophic studies postoperatively. The degree of tissue overgrowth in hypertrophic cases was investigated, as was its association with patient clinical outcome at 24 months after surgery.
Of the 180 patients, 50 demonstrated a hypertrophic graft at 1 or more postoperative time points. This included 9 grafts (5.0%) at 3 months and 32 grafts (18.7%) at 12 months. At 24 months, 47 grafts (26.1%)-43 (32.1%) tibiofemoral and 4 (8.7%) patellofemoral-were hypertrophic. Patients with hypertrophic grafts at 24 months (n = 47) were younger (P = .051), they had a lower body mass index (BMI; P = .069), and significantly fewer of them had patellofemoral grafts (P = .007) compared with patients who had grafts with full (100%) tissue infill (n = 61). There were no significant differences in any of the KOOS subscales between patients with graft hypertrophy or full (100%) tissue infill at 24 months after surgery, while the severity of graft hypertrophy was not associated with KOOS subscales at 24 months.
Hypertrophic grafts after MACI were common and continued to develop through to 24 months after surgery. Hypertrophic growth was associated with being younger and having a lower BMI, was more common on the femoral condyles, and overall was not associated with clinical outcome at 24 months after surgery. However, further research with longer term follow-up is required to evaluate the effect of persistent hypertrophy on graft stability and to assess the use of early surgical intervention to prevent such failure.
在骨膜移植、胶原覆盖和基质诱导的自体软骨细胞植入术(MACI)后,移植物肥大是一种常见现象。
目的/假设:本研究的目的是调查MACI术后24个月时移植物肥大的发生率、发展情况及程度。假设是移植物肥大与术后24个月的临床结果无关。
病例系列研究,证据等级为4级。
本研究纳入了180例连续接受膝关节MACI手术的患者(男113例,女67例)。所有患者均使用膝关节损伤和骨关节炎结局评分(KOOS)进行临床评估,并在术后3个月、12个月和24个月接受磁共振成像(MRI)检查。研究了与解剖学移植物部位相关的肥大发生率,以及术后肥大研究的进展变化。对肥大病例中的组织过度生长程度进行了研究,并探讨了其与术后24个月患者临床结果的相关性。
180例患者中,50例在术后1个或多个时间点出现移植物肥大。其中包括3个月时9例移植物(5.0%)和12个月时32例移植物(18.7%)。在24个月时,47例移植物(26.1%)出现肥大,其中43例(32.1%)位于胫股关节,4例(8.7%)位于髌股关节。与移植物组织完全填充(100%)的患者(n = 61)相比,术后24个月出现移植物肥大的患者(n = 47)更年轻(P = 0.051),体重指数(BMI)更低(P = 0.069),且髌股关节移植物的患者明显更少(P = 0.007)。术后24个月时,移植物肥大患者与移植物组织完全填充(100%)的患者在任何KOOS子量表上均无显著差异,而移植物肥大的严重程度与术后24个月的KOOS子量表无关。
MACI术后移植物肥大很常见,并且在术后24个月仍持续发展。肥大生长与年轻和较低的BMI相关,在股骨髁上更常见,总体而言与术后24个月的临床结果无关。然而,需要进行更长期随访的进一步研究,以评估持续性肥大对移植物稳定性的影响,并评估早期手术干预预防此类失败的作用。